Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0119)
Name |
T-2 Toxin
|
||||
---|---|---|---|---|---|
Synonyms |
T-2 TOXIN; T2 Toxin; 21259-20-1; T2-Trichothecene; Mycotoxin T-2; Insariotoxin; Isaritoxin; T-2 mycotoxin; Fusariotoxine T2; Fusariotoxin T-2; Toxin T2; Fusariotoxin T 2; I3FL5NM3MO; T 2 Toxin; Fusariotoxin T2; Toxin T 2; 3-Hydroxy-4,15-diacetoxy-8-(3-methylbutyryloxy)-12,13-epoxy-delta-9-trichothecene; T-2 Toxin 100 microg/mL in Acetonitrile; NSC 138780; NSC-138780; T 2 mycotoxin; T-2 Lienomycin; ZBA; Scirpenol, 8-(3-methylbutyryloxy)-diacetoxy-; 12,13-Trichothecene; T(sub 2)-Trichothecene; UNII-I3FL5NM3MO; T-2 TOXIN [HSDB]; T-2 TOXIN [MI]; T-2 Toxin, reference material; CCRIS 3456; CHEBI:9381; CHEMBL152423; SCHEMBL7536392; DTXSID6021298; T2-TRICHOTHECENE [IARC]; HSDB 3544; EINECS 244-297-7; T-2 Toxin, >=98.0% (TLC); 8-(3-Methylbutyryloxy)-diacetoxyscirpenol; BT162749; Trichothec-9-ene-3,4,8,15-tetrol, 12,13-epoxy-, 4,15-diacetate 8-(3-methylbutanoate), (3alpha,4beta,8alpha)-; Q63392226; 4,15-Diacetoxy-8-(3-methylbutyryloxy)scirp-9-en-3-ol; T-2 Toxin, from Fusarium sp., powder, >=98% (HPLC); 8alpha-(3-Methylbutyryloxy)-4beta,15-diacetoxyscirp-9-en-3alpha-ol; 12,13-Epoxytrichothec-9-ene-3,4,8,15-tetrol 4,15-diacetate 8-(3-methylbutanoate); 12,13-Epoxytrichothec-9-ene-3-alpha,4-beta,8-alpha,15-tetrol 4,15-diacetate 8-isovalerate; 12,13-Epoxytrichothec-9-ene-3alpha,4beta,8alpha,15-tetrol, 4,15-diacetate 8-isovalerate; 3-Hydroxy-4,15-diacetoxy-8-(3-methylbutyryloxy)-12,13-epoxy-delta(sup 9)-trichothecene; 4,15-Diacetoxy-8-(3-methylbutyryloxy)-12,13-epoxy-delta-9-trichothecen-3-ol; 4beta,15-Diacetoxy-3alpha-hydroxy-8alpha-(3-methylbutyryloxy)-12,13-epoxytrichothec-9-ene; (3alpha,4beta,8alpha)-12,13-epoxy-4,15-diacetate 8-(3-methylbutanoate)trichothec-9-ene-3,4,8,15-tetrol; (3alpha,4beta,8alpha)-12,13-Epoxytrichothec-9-ene-3,4,8,15-tetrol 4,15-diacetate 8-(3-methylbutyrate); 3alpha-Hydroxy-4beta-15-diacetoxy-8alpha-(3-methylbutyryloxy)-12,13-epoxy-delta9-tricothecene; 4-beta,15-Diacetoxy-8-alpha-(3-methylbutyryloxy)-3-alpha-hydroxy-12,13-epoxytrichothec-9-ene; 4.BETA.,15-DIACETOXY-8.ALPHA.-(3-METHYLBUTYRYLOXY)-12,13-EPOXYTRICHOTHEC-9-EN-3.ALPHA.-OL; 4beta,15-bis(acetyloxy)-3alpha-hydroxy-12,13-epoxytrichothec-9-en-8alpha-yl 3-methylbutanoate; Butanoic acid, 3-methyl-, (3.alpha.,4.beta.,8.alpha.,12.alpha.)-4,15-bis(acetyloxy)-12,13-epoxy-3-hydroxytrichothec-9-en-8-yl ester; Trichothec-9-ene-3-alpha,4-beta,8-alpha,15-tetrol, 12,13-epoxy-, 4,15-diacetate 8-isovalerate; Trichothec-9-ene-3alpha,4beta,8alpha,15-tetrol, 12,13-epoxy-, 4,15-diacetate 8-isovalerate
Click to Show/Hide
|
||||
Structure |
![]() |
||||
Formula |
C24H34O9
|
||||
IUPAC Name |
[(1S,2R,4S,7R,9R,10R,11S,12S)-11-acetyloxy-2-(acetyloxymethyl)-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-4-yl] 3-methylbutanoate
|
||||
Canonical SMILES |
CC1=CC2C(CC1OC(=O)CC(C)C)(C3(C(C(C(C34CO4)O2)O)OC(=O)C)C)COC(=O)C
|
||||
InChI |
InChI=1S/C24H34O9/c1-12(2)7-18(27)32-16-9-23(10-29-14(4)25)17(8-13(16)3)33-21-19(28)20(31-15(5)26)22(23,6)24(21)11-30-24/h8,12,16-17,19-21,28H,7,9-11H2,1-6H3/t16-,17+,19+,20+,21+,22+,23+,24-/m0/s1
|
||||
InChIKey |
BXFOFFBJRFZBQZ-QYWOHJEZSA-N
|
||||
PubChem CID |
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Health | ICD-11: N.A. | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | HEK-293T cells | Normal | Homo sapiens | CVCL_0063 |
NCI-H1299 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | |
Response regulation | SLC7A11 overexpression significantly rescued the enhanced ferroptosis caused by T-2 toxin. T-2 toxin induces ferroptosis by downregulating SLC7A11 expression. Ferroptosis mediates T-2 toxin-induced cytotoxicity by increasing ROS and downregulating SLC7A11 expression. | |||